Add BrightSurf on Google Email

Mary Ann Liebert, Inc./Genetic Engineering News


Is the US health care system a target for cyberterrorism?

The US healthcare system is a $2.5 trillion industry heavily reliant on the internet, making it a target for cyberterrorism. Experts predict a wave-like attack that could leave staff untrusting of electronic data and demoralize IT teams. To protect itself, the healthcare system must remain vigilant and implement better security measures.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalTelemedicine and e-Health·DateDec 17, 2012

Association of Environmental Engineering and Science Professors name Environmental Engineering Science as its official journal

The Association of Environmental Engineering and Science Professors (AEESP) has selected Environmental Engineering Science as its official journal, promoting innovative solutions to environmental problems. The journal will publish state-of-the-art studies on air, water, and land contamination and waste disposal.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalEnvironmental Engineering Science·DateDec 13, 2012

Are we closer to understanding the cause of deadly sepsis?

A growing body of literature suggests that alterations in regulatory T cell function may contribute to the development of sepsis. Manipulating these cells may offer a promising approach to treating patients with septic shock. The Journal of Interferon & Cytokine Research reviews the current understanding of this complex immune response.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalJournal of Interferon & Cytokine Research·DateNov 16, 2012

Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?

Researchers explored the benefits of adding radionuclide therapy to cancer treatment regimens for patients with advanced disease. Studies found improved tumor control rates and longer patient survival without significant side effects, suggesting a potential paradigm shift in cancer control.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalCancer Biotherapy and Radiopharmaceuticals·DateNov 13, 2012

Can diabetes devices be damaged by airport security scanners?

Research highlights the potential impact of airport security scanners on diabetes devices, including insulin pumps and continuous glucose monitoring systems. The Editorial calls for more research to understand and potentially repair this issue affecting hundreds of thousands of people worldwide who use insulin pump therapy.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalDiabetes Technology & Therapeutics·DateOct 24, 2012

Ongoing disparities in breastfeeding highlighted at Fourth Annual Summit on Breastfeeding

The Fourth Annual Summit on Breastfeeding highlighted ongoing disparities in breastfeeding, with only 44% of African-American women reporting breastfeeding compared to 66 and 68% for Hispanic and white women. The summit also explored the role of access to support, counseling, and equipment as a means to increase breastfeeding rates.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalBreastfeeding Medicine·DateOct 18, 2012

Disability caused by traumatic brain injury in children may persist and stop improving after 2 years

A recent study published in the Journal of Neurotrauma found that children who suffered moderate or severe traumatic brain injuries may still experience substantial functional disabilities and reduced quality of life two years after the injury. The authors suggest that a plateau is reached in recovery beyond this period.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalJournal of Neurotrauma·DateSep 18, 2012

Implementing a therapeutic hypothermia program for post-cardiac arrest in acute care hospitals

A study published in Therapeutic Hypothermia and Temperature Management found that therapeutic hypothermia can limit the devastating consequences of brain injury after cardiac arrest. The survey results show a wide variation in patient selection criteria for therapeutic hypothermia across New Jersey hospitals.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalTherapeutic Hypothermia and Temperature Management·DateAug 2, 2012

Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?

A recent study published in Cancer Biotherapy and Radiopharmaceuticals suggests that high-dose interleukin-2 (IL-2) should continue to be the initial treatment for patients with stage IV metastatic melanoma. The researchers recommend intensive IL-2 therapy as a viable option, either alone or in combination with newer therapeutic agents.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalCancer Biotherapy and Radiopharmaceuticals·DateJul 26, 2012